United States Giant Cell Arteritis Drugs Industry Booming: Latest Innovations, Pipeline Drugs & Revenue Forecast in 2025

DataM Intelligence unveils its latest report on the "Giant Cell Arteritis Drugs Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/giant-cell-arteritis-drugs-market?kb

Novartis Cosentyx Fails Phase 3 Trial in GCA:

Novartis' Cosentyx (secukinumab), an anti-IL-17 therapy, failed to achieve sustained remission in adults with newly diagnosed or relapsing giant cell arteritis (GCA) in the Phase 3 GCAptAIN study. Despite trends suggesting lower steroid use and reduced steroid-related toxicity, Cosentyx did not meet primary or secondary endpoints, limiting its potential for further GCA development.

GCA, an inflammatory disease affecting large and medium arteries, primarily in adults over 50, has traditionally relied on high-dose steroids, which control acute symptoms but carry long-term side effects. FDA-approved alternatives include Roche's Actemra (tocilizumab) and AbbVie's Rinvoq (upadacitinib), the latter approved as the first oral targeted therapy for GCA.

Cosentyx remains a blockbuster for Novartis in other indications, including psoriasis, psoriatic arthritis, and ankylosing spondylitis, generating over $6 billion annually, with patent protection in the US until 2032 and Europe until 2031.

Growth Drivers

Aging Population:

According to WHO data, by 2030, 1 in 6 people globally will be aged 60 or older, with the population increasing from 1 billion in 2020 to 1.4 billion, and expected to double to 2.1 billion by 2050.

Cardiovascular Disease:

As per the CDC, heart disease remains the leading cause of death in the U.S. across all genders and racial/ethnic groups, with one person dying from cardiovascular disease every 37 seconds.

Strategic Collaboration:

Kiniksa Pharmaceuticals and Hangzhou Zhongmei Huadong Pharmaceutical announced a partnership to develop and commercialize ARCALYST and mavrilimumab in the Asia-Pacific region. Phase 2 clinical trials of mavrilimumab for rheumatoid arthritis and giant cell arteritis successfully met primary and secondary endpoints with statistical significance.

List of Top Key Player:

Genentech, Inc., F. Hoffmann-La Roche Ltd, Biogen, Novartis AG, Aark Pharmaceuticals, Aetna Inc., Sartorius AG, Fresenius Kabi USA, Bio-Rad Laboratories, Inc and CELLTRION INC among others.

Industry Developments:

According to a Springer Open study, GCA occurs at an annual rate of 15-25 cases per 100,000 people, primarily affecting those over 50, with women twice as likely as men to develop the disease. The lifetime risk is 1% for women and 0.5% for men.

Market growth in the region is supported by favorable government reimbursement policies, increased R&D investments, and industry focus on clinical trials, product launches, and approvals.

For example, in May 2023, AbbVie presented Phase 2 results from the SLEek study evaluating upadacitinib (RINVOQ) alone and with ABBV-599 in adults with moderate to severe systemic lupus erythematosus (SLE). Upadacitinib is also in Phase 3 development for GCA, Takayasu arteritis, and SLE.

Additionally, in April 2024, Fresenius Kabi launched Tyenne (tocilizumab-aazg) in the U.S., a biosimilar of Actemra, indicated for autoimmune conditions including rheumatoid arthritis, GCA, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Forecast Projection:

The Global Giant Cell Arteritis Drugs Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.

Market Intelligence Research Process:

The Giant Cell Arteritis Drugs Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=giant-cell-arteritis-drugs-market

Key Segmentation:

By Drug Type: (Corticosteroids, Immune-suppressing Agents, Anti Coagulants, Biologics, Others)

By Route of Administration: (Oral, Intravenous, Subcutaneous,Others)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Global Growth Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Giant Cell Arteritis Drugs Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.

Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.

Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.

Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.

Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.

Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.

Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.

Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.

Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/giant-cell-arteritis-drugs-market?kb

FAQ's

Q1: What is the current size of the Giant Cell Arteritis Drugs Market and its future potential?

A: The Giant Cell Arteritis Drugs Market was valued at US$ 933.2 million in 2023 and is projected to surge to US$ 1859.5 million by 2031

Q2: How fast is the Giant Cell Arteritis Drugs Market expected to grow in the coming years?

A: The market is forecast to expand at a robust CAGR of 9% between 2025 and 2032, signaling strong global growth and investment potential.

Q3: Which regions are dominating the Giant Cell Arteritis Drugs Market and which are fastest-growing?

A: North America held around 43.2% of the global GCA drug market

Latest Trends

In April 2024, AbbVie reported positive top-line results from the Phase 3 SELECT-GCA study, showing that upadacitinib (RINVOQ 15 mg once daily) combined with a 26-week steroid taper achieved sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA).

In March 2023, EULAR recommended weekly tocilizumab 162 mg for new or relapsing GCA cases, used alongside glucocorticoids that should be gradually tapered, as per updated guidance on interleukin-6 inhibitors.

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.